Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc.AMLX · Entity 259 | Chief Legal Officer | September 10, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amylyx Pharmaceuticals, Inc.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 190,838 |
Ending reported balance
After 2026-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-10 · Sale · Disposed 9,525 · Balance 190,849 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $33.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 2 · 2026-09-10 · Sale · Disposed 11 · Balance 190,838 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $33.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 14, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 11 | $33.34 | $366.74 |
DisclosureSEC source: 0001193125-26-390508 · ownership.xml · nonDerivative · entry 2 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,838 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 9,525 | $32.46 | $309,139.59 |
DisclosureSEC source: 0001193125-26-390508 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,849 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $33.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 18, 2026 Filed Aug 21, 2026 01:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantCommon Stock | 21,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-359677 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,374 F1 · shares: The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 15,000 | $17.61 | $264,121.50 |
DisclosureSEC source: 0001193125-26-301996 · ownership.xml · nonDerivative · entry 2 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,090 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.15 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 15,000 | $18.32 | $274,746.00 |
DisclosureSEC source: 0001193125-26-301996 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,090 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.92 to $18.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 111,990 | $0.00 Strike: $14.10 | $0.00 |
DisclosureSEC source: 0001193125-26-098439 · ownership.xml · derivative · entry 2 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,990 Underlying: Common Stock · 111,990 shares Expires 2036-03-05 F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantCommon Stock | 74,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-098439 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,090 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 6,844 | $14.52 | $99,378.30 |
DisclosureSEC source: 0001193125-26-091436 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,430 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.400 to $15.070. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 3,419 | $14.14 | $48,352.18 |
DisclosureSEC source: 0001193125-26-071460 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,274 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.030 to $14.220. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:05 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 3,448 | $14.65 | $50,515.61 |
DisclosureSEC source: 0001193125-26-037548 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,693 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.470 to $14.810. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:15 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 8,828 | $14.58 | $128,668.98 |
DisclosureSEC source: 0001193125-25-228342 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,141 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.355 to $15.075. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 20:20 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 15,000 | $8.34 | $125,046.00 |
DisclosureSEC source: 0000950170-25-108912 · ownership.xml · nonDerivative · entry 2 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,969 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.13 to $8.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:20 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 15,000 | $8.07 | $121,102.50 |
DisclosureSEC source: 0000950170-25-108912 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,969 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.82 to $8.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:01 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-077677 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,969 F1 · kind: Represents a bona fide gift for no consideration. F1 · shares: Represents a bona fide gift for no consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:12 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 9,192 | $3.48 | $31,954.15 |
DisclosureSEC source: 0000950170-25-049560 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,969 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 00:34 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 95,777 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-25-036717 · ownership.xml · derivative · entry 2 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,777 Underlying: Common Stock · 95,777 shares Expires 2035-03-05 F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 00:34 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantCommon Stock | 63,851 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-036717 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,161 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:32 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 1,611 | $3.12 | $5,022.29 |
DisclosureSEC source: 0000950170-25-033717 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,310 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.10 to $3.165. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 4,169 | $3.15 | $13,144.86 |
DisclosureSEC source: 0000950170-25-027833 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,921 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.14 to $3.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:58 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 3,678 | $3.49 | $12,839.16 |
DisclosureSEC source: 0000950170-25-014620 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,090 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.46 to $3.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 22:48 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 8,709 | $3.20 | $27,840.06 |
DisclosureSEC source: 0000950170-24-111805 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,768 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.12 to $3.235. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 15, 2024 Filed May 16, 2024 23:36 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 10,455 | $1.88 | $19,654.35 |
DisclosureSEC source: 0000950170-24-061293 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,477 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.82 to $1.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 16, 2024 Filed Apr 19, 2024 00:20 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0000950170-24-045695 · ownership.xml · derivative · entry 2 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2034-04-15 F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on April 16, 2025, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| April 16, 2024 Filed Apr 19, 2024 00:20 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantCommon Stock | 80,560 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-045695 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,932 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest as follows: 33% on September 30, 2024, 33% on March 31, 2025 and 34% on September 30, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:05 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 1,540 | $18.73 | $28,840.97 |
DisclosureSEC source: 0000950170-24-027921 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,372 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.62 to $18.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 23:13 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $17.56 | $0.00 |
DisclosureSEC source: 0000950170-24-022400 · ownership.xml · derivative · entry 2 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2034-02-25 F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 23:13 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantCommon Stock | 36,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-022400 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,912 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:59 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 2,838 | $18.76 | $53,230.66 |
DisclosureSEC source: 0000950170-24-021472 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,245 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.61 to $19.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 6,164 | $20.88 | $128,686.44 |
DisclosureSEC source: 0000950170-23-043242 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,083 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.41 to $21.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:07 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-023240 · ownership.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,247 Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 82,500 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009177 · doc4.xml · derivative · entry 2 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2033-03-16 F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantCommon Stock | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009177 · doc4.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,747 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:42 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 3,586 | $34.49 | $123,671.82 |
DisclosureSEC source: 0000899243-23-006418 · doc4.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,414 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.25 to $34.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 22, 2022 Filed Feb 28, 2022 22:05 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 182,000 | $0.00 Strike: $28.24 | $0.00 |
DisclosureSEC source: 0000899243-22-008101 · doc4.xml · derivative · entry 2 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,000 Underlying: Common Stock · 182,000 shares Expires 2032-02-22 F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest 1/48 monthly over the 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| February 22, 2022 Filed Feb 28, 2022 22:05 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantCommon Stock | 41,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-008101 · doc4.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.